Adam Bagg, M.D., University of Pennsylvania, Philadelphia, PA and Daniel A. Arber, M.D., Stanford University, Stanford, CA
Molecular studies are being increasingly used in the routine evaluation of all types of pathology specimens. This is best developed in the sphere of hematopathology, and this course will use leukemias and lymphomas as a paradigm to discuss their application in routine practice. The intent is not to comprehensively review all of neoplastic hematopathology and molecular pathology; thus, participants are expected to have some general knowledge in these areas. The course is intended primarily for general pathologists, as well as specialists and trainees.
The specific educational objectives are to: (1) briefly overview the molecular pathology tools currently routinely used in hematopathology, highlighting their advantages and disadvantages; (2) summarize some of the biology underlying the molecular mechanisms of leukemia and lymphoma, and how this is then applied to in practice; (3) provide a rational approach as to when to order molecular assays, using a case-study approach; (4) discuss the role of these studies not only in diagnosis, but also in prognosis and monitoring [minimal residual disease]; (5) illustrate the pitfalls, both technical and biologic, of molecular assays; (6) emphasize the need to integrate these data with other pathologic studies; and (7) provide a brief overview of the future of molecular diagnostics in hematopathology.
A limited number of glass slides (of biopsies and smears), with case histories and questions focusing on which molecular assays to order, and how to interpret the results, will be available for distribution prior to the course. A detailed and practical handout will be distributed at the course, and after the meeting all participants will be mailed a CD of pertinent images from the presentation. (Last scheduled presentation)